AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04343196 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Diagnostic Angiography (DSA or DVA based on randomization result)
Description: After radial/brachial/femoral artery puncture using Seldinger technique, the investigators first position a pigtail catheter above the level of the renal arteries. With Siemens Artis Zee Pure DSA machine the examiner will use a postero-anterior X-ray view for the first image, which is an aortography of some part of the iliac system. Then, the catheter will be repositioned to the aortic bifurcation and 15-18 mL contrast media (CM) with 9-10 mL/s flow for the ilio-femoral region will be injected. All of the following image series will be made from this catheter position, with a 9 mL/s flow rate. In cases for when the recorded image series will be inconclusive, image series with left/right oblique position will be recorded. All femoro-popliteal images will be recorded with 10-16 ml CM and crural regions with 12-22mml. DSA images will be calculated from all series on a dedicated Syngo workstation and used for diagnosis. DVA images will be calculated by the Kinepict Medical Imaging Tool
Study NCT02441621 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: passive leg raising
Description: The passive leg raising maneuver (PLR) involves a leg elevation up to 45° with the trunk in a horizontal position and is performed to induce hemodynamic effects by a volume challenge, turning unstressed blood volume to stressed volume proportional to body size.
Study NCT02441621 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: premedication
Description: patients receive premedication with midazolam 7.5 mg p.o.
Study NCT02441621 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: intubation and mechanical ventilation
Description: After induction of anesthesia with sufentanil (0.5 µg/kg) and propofol (1.5 mg/kg), orotracheal intubation is facilitated with rocuronium (0.6 mg/kg). Anesthesia is maintained with sufentanil (1 µg/kg/h) and propofol (3 mg/kg/h) and patients are ventilated with an oxygen/air mixture in volume-controlled mode, using a tidal volume of 8 ml/kg related to the ideal body weight. Positive end-expiratory pressure is set at 5 cmH2O.
Study NCT02441621 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: central venous catheter
Description: a central venous catheter in the right or left internal jugular vein.
Study NCT02441621 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: arterial catheter
Description: Continuous monitoring is performed including electrocardiogram, radial arterial pressure catheter
Study NCT02441621 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: transesophageal echocardiography
Description: Before placement of a transpulmonary thermodilution catheter a transesophageal echocardiography (TOE) is performed. TOE is used to detect diastolic dysfunction of the left ventricle and to exclude right ventricular dysfunction.
Study NCT02441621 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: transpulmonary thermodilution catheter
Description: In presence of left ventricular dysfunction a transpulmonary thermodilution catheter is placed in the femoral artery and connected to a PiCCO2 monitor (PiCCO2, Pulsion Medical Systems, Munich, Germany).
Study NCT01034358 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human Papillomavirus Vaccine
Description: 0.5mL intramuscular for 3 doses at 0, 2, and 6 months
Study NCT01883713 — intervention group
Intervention type: DEVICE
Intervention: Brain Oximetry
Description: Non invasive brain oximeter will be applied on the patient's forehead to monitor the brain oxygen saturation throughout the surgery.
Study NCT01686438 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy for insomnia
Description: A behavioral modification program consisting of 6 clinic sessions focused on sleep hygiene, stimulus control, sleep restriction, and cognitive restructuring.
Study NCT01686438 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive behavioral therapy for insomnia
Description: A behavioral modification program consisting of 6 clinic sessions focused on sleep hygiene, stimulus control, sleep restriction, and cognitive restructuring.
Study NCT00459420 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine 100-200 mg BID
Description: Caffeine 100 mg BID for three weeks, then 200 mg BID for three weeks, then 100 mg BID for 1 week, then placebo
Study NCT00459420 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT00759317 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: venlafaxine (Effexor)
Description: Matching capsules containing either venlafaxine 37.5 mg. or placebo will be prepared by the UCLA Pharmacy for the initial phase of the study. For the open-label phase of the study, subjects will receive the medication and dosage that is clinically indicated by the subject's primary physician in the community. After a one-week placebo lead-in, subjects will be randomly assigned to receive one capsule of either venlafaxine or placebo, with the dosage increase every two days until subjects receive four capsules daily (subjects will achieve a dose 150 mg. of venlafaxine after 7 days). The first dose will be administered in the morning, with subsequent capsules added on a b.i.d. schedule.
Study NCT00759317 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: venlafaxine (Effexor)
Description: Matching capsules containing either venlafaxine 37.5 mg. or placebo will be prepared by the UCLA Pharmacy for the initial phase of the study. For the open-label phase of the study, subjects will receive the medication and dosage that is clinically indicated by the subject's primary physician in the community. After a one-week placebo lead-in, subjects will be randomly assigned to receive one capsule of either venlafaxine or placebo, with the dosage increase every two days until subjects receive four capsules daily (subjects will achieve a dose 150 mg. of venlafaxine after 7 days). The first dose will be administered in the morning, with subsequent capsules added on a b.i.d. schedule.
Study NCT03916861 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bioelectrical Impedance Analysis
Description: We use Inbody S20 analysis to measure fluid status before each hemodialysis session to guide fluid removal.
Study NCT03916861 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Physician-guided
Description: This intervention used physical examination as guided to adjust fluid therapy together with the chart record of intake and output per day
Study NCT04449315 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Young Living Lavender Essential Oil
Description: For qualified patients one to two drops of hospital approved essential oil will be placed on a 4X4 gauze and will be offered to the patient during their infusion visit. This gauze will be placed in a sealable clear plastic bag and the patient will be instructed to use one sniff at a time.
Study NCT01686386 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Phase I: dose escalation of Bendamustine Phase II: Dexamethasone will be given in combination with the MTD of Bendamustine and Lenalidomide in cycles lasting 28 days.
Study NCT01686386 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Phase I: dose escalation of Lenalidomide Phase II: Dexamethasone will be given in combination with the Maximum Tolerated Dose (MTD) of Bendamustine and Lenalidomide in cycles lasting 28 days.
Study NCT01686386 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Phase I and Phase II Dexamethasone fixed dose 40 mg/die
Study NCT01906918 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: IRPC, Remote preconditioning
Description: The patients will be submitted to 5 minutes of upper limb compression by cuff followed by 5 minutes of reperfusion. This cycle will be repeated 4 times.
Study NCT04991194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 5-1058
Description: Each subject was administered either 1200 mg (Part 1) or 400 mg (Part 2) BIA 5-1058 od for 10 days, in fasting conditions for 8 hours \[Day (D)2 to D9\] or 10 hours (D1 and D13), and remained fasted for 2 hours (D2 to D9) or 4 hours (D1 and D13) post-dose. The formulation was tablets 100 mg and the mode of administration was oral.
Study NCT01555645 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress management, in two steps
Description: All patients start at the first step of the intervention program with a two hours psychoeducation in stress management. Patients, who don't report a decrease in stress related symptoms, after the first step will be offered an intensive stress management, either in individual or group format. Components included in the intervention concern 1) basic knowledge about cancer, treatment, healthy living and stress reactions, 2) self-awareness with help of diary for thoughts, feelings and behavior 3) instruction in various techniques on how to express negative feelings, how to communicate with others more effectively, how to change behaviors related to stress 4) training these techniques in real-life situations 5) cognitive restructuring 6) spirituality, derived from cognitive behavior therapy.
Study NCT03525522 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nd:YAG Laser
Description: Three sessions of Nd:YAG treatment every two weeks.
Study NCT03525522 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical corticosteroid Diprosone
Description: 3 months of topical corticosteroids Diprosone
Study NCT04308850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D drops
Description: Vitamin D-deficient CD patients are divided into two groups, one group is given orally with Vitamin D drops 400IU / d, while the other group do not interfere.
Study NCT01931722 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Branched chain amino acid
Description: seven graded intakes of a BCAA (branched chain amino acid) mixture from 50 to 350 mg.kg-1.d-1 will be used to measure BCAA requirement
Study NCT01931722 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Strength training
Description: Strength training will include a split-training program using all major muscle groups of the body on a three day on, one day off protocol. Muscle areas targeted on each training day will be as follows: Day1: chest, shoulder, triceps; Day2: back, biceps; Day3: legs and calfs; Day4: will be a rest day. On Day5: this cycle will begin again. A combination of free weights and machines will be used for each training day. Progressive overload protocol will be applied where the load used by every participant will be adjusted bi-weekly based on their 70% of 1 repetition maximum (maximum weight that can be lifted only one time). Instruction will be provided for all exercises and professional trainers will oversee all training sessions.
Study NCT04673201 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Viscotrabeculotomy Versus trabeculectomy with MMC
Description: Viscotrabeculotomy involved the creation of a partial thickness scleral flap, followed by localization of Schlemm's canal by radial incisions.High viscosity sodium hyaluronate was injected into Schlemm's canal.Trabeculotomy was completed using the standard metal Harm's trabeculotome.The scleral flap was then secured and conjunctival closure ensued.Trabeculectomy technique involved a creation of a limbal-based conjunctival flap, followed by creation of a half-thickness sclera flap. MMC was applied underneath the conjunctival flap.The procedure was completed with both sclera and conjunctiva closed by 10/0 nylon sutures.
Study NCT03979768 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diabetes risk assessment service in Norwegian community pharmacies
Description: Two pharmacists at each pharmacy were trained to perform risk assessments and counselling. During six months, pharmacy customers equal or above 45 years old, wishing to participate contacted the pharmacy staff. Participants completed a validated diabetes risk test and a background questionnaire including a validated instrument for self-rated health.
Study NCT02807987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS-3150
Description: CS-3150 1.25 to 2.5, 5mg, orally
Study NCT04034290 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GamFluVac
Description: The drug is a vaccine that induces high-level immunity against influenza A viruses
Study NCT04034290 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01526174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Golimumab
Description: Intratympanic injection 0.3ml First Arm: 1 injection Second Arm: 4 injections
Study NCT04512781 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Control Cannula - Prosoft Cannula - Unicorn Cannula
Description: The purpose of this intervention is to evaluate the efficacy of a conventional legacy cannula design to provide targeted relief of dyspnea. The purpose of this intervention is to evaluate the efficacy of a next generation cannula to provide relief of dyspnea.
Study NCT04512781 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Control Cannula - Unicorn Cannula - Prosoft Cannula
Description: The purpose of this intervention is to evaluate the efficacy of a conventional legacy cannula design to provide targeted relief of dyspnea. The purpose of this intervention is to evaluate the efficacy of a next generation cannula to provide relief of dyspnea.
Study NCT02723981 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: COMBO-Stent
Description: The OrbusNeich COMBO Bio-engineered Sirolimus Eluting Stent (COMBO Stent) consists of a 316L stainless steel alloy abluminally coated with a biocompatible, biodegradable poly-mer containing sirolimus. Covalently attached to the surface of the stent is a layer of murine, monoclonal, anti-human CD34 antibody. The antibody specifically targets circulatory CD34+ cells (endothelial progenitor cells) thus favoring endothelialization.
Study NCT02723981 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel, Vitamin K Antagonist, Rivaroxaban, Dabigatran
Description: Anticoagulant medication after stent Implantation: (N)OAC and clopidogrel for 3 months followed by (N)OAC
Study NCT02723981 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Any drug eluting stent oder bare metal sent
Description: Implantation of traditional bare metal stents and/or drug eluting stents (any device approved on the market, implanted according to CE marking and IFU) and medication regimen in accordance with ESC Guidelines
Study NCT02862275 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT02723981 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ASA, Clopidogrel, Vitamin K Antagonist, Rivaroxaban, Dabigatran
Description: A combination of antiplatelet and anticoagulant therapy according to ESC guidelines (2014)
Study NCT00804856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Volasertib
Description: Volasertib administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).
Study NCT04438421 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine mouthwash
Description: Subjects will then be given Chlorhexidine 0.2%mouthwash, as an active comparator, to be used twice a day after meals and after normal oral hygiene procedures. Next, the subjects will be re-evaluated after 3 days and after one month.
Study NCT04438421 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will then be given a placebo product to be used twice a day after meals and after normal oral hygiene procedures. Next, the subjects will be re-evaluated after 3 days and after one month.
Study NCT03754153 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Balanced Binocular Viewing (BBV)
Description: The dose of BBV therapy will be one hour a day or 2x30 min/day (depending on child's attention span and/or need to implement the treatment around the family daily routine).
Study NCT03754153 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Therapy - Occlusion (patching) or blurring (atropine)
Description: The prescribed dose of occlusion treatment / patching (parental choice) will depend on the severity of amblyopia, as by current clinical practice based on PEDIG studies
Study NCT01883570 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: training in visual search strategy
Study NCT01883570 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: access to a library of chest x-rays without search strategy
Study NCT03615027 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dementia-specific advance care planning
Description: see detailed description
Study NCT01400646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Description: Type=exact number, unit=mg, number=20, form=tablet, route=oral use. One tablet once daily for 5 days (Treatment Period 1, Days 1-7).
Study NCT02360839 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: EUS-guided fine needle biopsy sampling (EUS-FNB)
Description: Dual sampling with EUS-FNA and EUS-FNB in a randomized order.
Study NCT01400646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin
Description: Type=exact number, unit mg, number=10, form=tablet , route=oral use. One tablet for 2-4 days (Treatment Period 1, Day 6 up to Day 11).
Study NCT01400646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin K
Description: Type=exact number, unit=mg, number=1, form=oral solution, route=oral use. 1 mg dose for 1 day (Treatment Period 1, Day 12).
Study NCT01400646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin K
Description: Type=exact number, unit=mg, number=5, form=oral solution, route=oral use. 5 mg dose for 1 day (Treatment Period 2, Day 7).
Study NCT01400646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin
Description: Type-exact number, unit=mg, number=10, form=tablet, route=oral use. Tablet(s) administered once daily for 2-4 days (Treatment Period 2, Day 1 up to Day 6)
Study NCT01400646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin
Description: Type=range, unit=mg, number=0-15, form=tablet, route=oral use. Tablet(s) taken once daily for up to 4 days after Warfarin 10 mg administered as monotherapy for 2-4 days (Treatment Period 1).
Study NCT01400646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin
Description: Type=range, unit=mg, number=0-15, form=tablet, route=oral use. Tablet(s) taken once daily for up to 4 days after Warfarin 10 mg administered as monotherapy for 2-4 days (Treatment Period 2).
Study NCT02712502 — intervention group
Intervention type: DRUG
Intervention: Levofloxacin
Description: * Levofloxacin (Levolet) 750 mg (500 mg Levolet P + P Levolet 250 mg) 1 times a day. The course of treatment is 5 days.~* Decongestants: xylometazoline 2 doses in each nostril two times daily - the first 5 days, then if necessary.
Study NCT02712502 — intervention group
Intervention type: DRUG
Intervention: Amoxicillin-Potassium Clavulanate Combination
Description: Amoxicillin-Potassium Clavulanate Combination (875 mg of amoxicillin trihydrate, potassium clavulanate salt + 125 mg), 2 times a day. The course of treatment 10 days.~• Decongestants: xylometazoline 2 doses in each nostril two times daily - the first 5 days, then if necessary.
Study NCT03366714 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: nasal CPAP support with RAM cannula
Description: Patients with respiratory distress syndrome who do not need intubation in the delivery room. This groub will be provided with non-invasive respiratory support RAM cannula.
Study NCT03366714 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: nasal CPAP support with Hudson cannula
Description: Patients with respiratory distress syndrome who do not need intubation in the delivery room. This groub will be provided with non-invasive respiratory support Hudson cannula.
Study NCT03394495 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BCE Combination group
Description: The combination intervention programme consists of a weekly exercise training sessions and 6 sessions of Behavioral Change Enhancement (BCE) programme.
Study NCT02366962 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ASP7374
Description: subcutaneous
Study NCT01994343 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Global posture reeducation
Description: An assessment of the women is performed using global posture reeducation.
Study NCT03797287 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tensor Tunnler
Description: Create the bone tunnels during the arthroscopic rotator cuff repair procedure
Study NCT03797287 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anchor Rotator Cuff Repair
Description: The suture anchors (Smith and Nephew PEEK Helicoil Anchor) are inserted in bone and the sutures are then used to sew the tendons to bone arthroscopically.
Study NCT01051739 — intervention group
Intervention type: PROCEDURE
Intervention: Comparison of four visual field testing strategies
Description: We compared the ability of four perimetric strategies to detect visual field change in the glaucoma arm.
Study NCT03489213 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dietary Intervention
Description: Participants randomized to the DGA/AICR group will receive plant-based diet education, garden access and health coaching for 5 months. The sessions are offered every other week.
Study NCT03489213 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Intervention
Description: Participants randomized to the DGA/AICR group will receive plant-based diet education, garden access and health coaching for 5 months. The sessions are offered every other week.
Study NCT03489213 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Intervention
Description: Participants will wear a FitBit every day and monitor daily physical activity.